When is PARP inhibitor therapy recommended for triple-negative breast cancer?

Triple-negative breast cancer lacks three commonly targeted receptors, so treatment decisions rely on other tumour and inherited features. PARP inhibitors target a DNA-repair weakness associated with some inherited BRCA-related changes. The team considers whether the cancer is early or advanced, whether surgery or chemotherapy has already occurred, the purpose of treatment, blood counts, kidney function, and other medicines. Testing a tumour is not the same as checking for an inherited change, and genetic counselling may help explain the result.

Ask whether inherited BRCA-related testing is appropriate and how the result would change your options. Give the oncology team your previous chemotherapy, surgery, and radiation details, plus any history of anaemia or kidney problems. If treatment is offered, follow the dosing schedule and attend monitoring visits. Tell the team promptly about fever, unusual bruising, or severe tiredness.

Seek urgent advice for fever, signs of infection, unexpected bleeding, severe shortness of breath, chest pain, or weakness that interferes with normal activities. These symptoms need assessment during cancer treatment. Ask in advance which service to call outside clinic hours and keep the medicine packaging available if emergency care is needed.

Ask whether the treatment is intended before or after surgery, for active disease, or as maintenance; which inherited result supports it; and how benefit will be checked. Ask about blood-test timing, common side effects, interactions, pregnancy considerations, and whether the result has implications for relatives.